title: The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA.
authors.affiliation: Department of Immunology, University of Constance, 78457 Constance, Germany. peter.oehlschlaeger@uni-konstanz.de
authors.forename: Peter
authors.initials: P
authors.lastname: Ohlschläger
authors.forename: Elmar
authors.initials: E
authors.lastname: Spies
authors.forename: Gerardo
authors.initials: G
authors.lastname: Alvarez
authors.forename: Michael
authors.initials: M
authors.lastname: Quetting
authors.forename: Marcus
authors.initials: M
authors.lastname: Groettrup
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D002460:Cell Line; D018899:CpG Islands; D018274:Electroporation; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D050725:Papillomavirus E7 Proteins / Q000235:genetics / Q000276:immunology*; D010957:Plasmids; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000502:physiology*; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D050725:Papillomavirus E7 Proteins; C495370:Tlr9 protein, mouse; D051217:Toll-Like Receptor 9; D019444:Vaccines, DNA; C059731:oncogene protein E7, Human papillomavirus type 16